Kirkland, Wachtell Advise On AbbVie’s $63B Merger With Allergan

Kirkland & Ellis advised AbbVie Inc. in its $63 billion cash and stock purchase of Botox-maker Allergan Inc., which was represented by Wachtell in one of the largest mergers in the pharmaceutical industry this year.

The merger will allow AbbVie, maker of top-selling rheumatoid arthritis injection Humira, to diversify its market portfolio. The deal would create a combined company with about $48 billion in sales, making it one of the biggest companies in the healthcare industry.

The deal is expected to close in early 2020.

Kirkland has represented Chicago-based AbbVie in a variety of matters over the years. Most recently ...